Recent developments in drug discovery against the protozoal parasites Cryptosporidium and Toxoplasma

Bioorg Med Chem Lett. 2017 Apr 1;27(7):1491-1501. doi: 10.1016/j.bmcl.2017.01.046. Epub 2017 Jan 17.

Abstract

Apicomplexan parasites cause some of the most devastating human diseases, including malaria, toxoplasmosis, and cryptosporidiosis. New drug discovery is imperative in light of increased resistance. In this digest article, we briefly explore some of the recent and promising developments in new drug discovery against two apicomplexan parasites, Cryptosporidium and Toxoplasma.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiprotozoal Agents / pharmacology*
  • Antiprotozoal Agents / therapeutic use
  • Apoptosis / drug effects
  • Cryptosporidiosis / drug therapy
  • Cryptosporidiosis / parasitology
  • Cryptosporidium / drug effects*
  • Cryptosporidium / enzymology
  • Diazepam Binding Inhibitor / antagonists & inhibitors
  • Drug Discovery
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Mice
  • Toxoplasma / drug effects*
  • Toxoplasma / enzymology
  • Toxoplasmosis / drug therapy
  • Toxoplasmosis / parasitology

Substances

  • Antiprotozoal Agents
  • Diazepam Binding Inhibitor
  • Enzyme Inhibitors